Jardiance to Reduce CVD in Type 2 Diabetes
Drug Alerts , Featured , News / December 9, 2016

The FDA approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease. Death from cardiovascular disease is 70 percent higher in adults...

Skip to toolbar